This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Amgen (AMGN) concluded the recent trading session at $331.29, signifying a +0.1% move from its prior day's close.
The Zacks Analyst Blog NVIDIA, Meta and Amgen Galaxy Gaming
by Zacks Equity Research
NVIDIA, Meta and Amgen Galaxy Gaming are included in this Analyst Blog.
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Amgen (AMGN) stood at $330.97, denoting a -1.4% change from the preceding trading day.
Q2 Earnings Season Scorecard, Economic Outlook and Analyst Reports for NVIDIA, Meta & Others
by Sheraz Mian
Today's Research Daily features the Q2 earnings season scorecard and fresh research reports on NVIDIA (NVDA), Meta (META), Amgen and others.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Amgen (AMGN) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Amgen (AMGN) reachead $330.83 at the closing of the latest trading day, reflecting a +1.77% change compared to its last close.
Pfizer (PFE) Moves Forward With Once-Daily Obesity Pill Study
by Zacks Equity Research
Pfizer (PFE) is set to move forward with the development of a once-daily formulation of danuglipron, its GLP-1 candidate for obesity.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?
by Kinjel Shah
Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.
Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's
by Zacks Equity Research
Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) reachead $311.46 at the closing of the latest trading day, reflecting a +0.19% change compared to its last close.
Beat the Market Like Zacks: Carvana, Adobe, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
by Sundeep Ganoria
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Take the Zacks Approach to Beat the Markets: NVIDIA, Seagate, Amkor in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
The Zacks Analyst Blog Highlights Chevron, Amgen, Philip Morris, Hurco and Perma-Pipe
by Zacks Equity Research
Chevron, Amgen, Philip Morris, Hurco and Perma-Pipe are included in this Analyst Blog.
Why Amgen (AMGN) Outpaced the Stock Market Today
by Zacks Equity Research
Amgen (AMGN) closed at $319.31 in the latest trading session, marking a +0.36% move from the prior day.
Top Stock Reports for Chevron, Amgen & Philip Morris
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Amgen Inc. (AMGN) and Philip Morris International Inc. (PM), as well as two micro-cap stocks Hurco Companies, Inc. (HURC) and Perma-Pipe International Holdings, Inc. (PPIH).
Beat the Market Like Zacks: Freshpet, AudioEye, Walmart in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $309.89, moving +1.27% from the previous trading session.
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.